Bristol-Myers Squibb to acquire Celgene in $74bn deal

03-01-2019

Bristol-Myers Squibb to acquire Celgene in $74bn deal

miodrag ignjatovic / iStockphoto.com

American pharmaceutical company Bristol-Myers Squibb (BMS) has announced it is purchasing drug manufacturer Celgene in a $74 billion deal.


Bristol-Myers Squibb, Celgene, merger, cancer drug, biopharmaceuticals, inflammation, cancer

LSIPR